Anaesthetic drugs & techniques

Tolerability and efficacy profile of S-ketamine compared with racemic ketamine in surgical patients, a prospective observational before-and-after study in the perioperative setting

BJA OpenPublished Prospective observational before-and-after study

Main finding · HallucinationsResult — go to the resultRisk difference 1.34% 95% CI −0.50 to 2.90

Authors' conclusion

S-Ketamine demonstrated a safer profile compared with Ra-Ketamine, including fewer psychodysleptic side effects and possible superior analgesic efficacy

Study context

Population
Patients receiving ketamine during anaesthesia for any type of surgery, 4 APHP Sorbonne Universite hospitals, Paris, 19 February to 22 March 2024; persistent sedation after surgery excluded783 included
Participants
447 vs 339
Exposure
Racemic ketamine vs S-ketamine
  • Ra-Ketaminen = 447reference
  • S-Ketaminen = 339
Outcome
Occurrence of hallucination, as a proxy for ketamine's tolerance
Methodological detailsmulticentre, before-after (institutional switch from Ra- to S-Ketamine)
  • Multicentre
  • Before-after (institutional switch from Ra- to S-Ketamine)

Main finding

Hallucinations

Risk difference

1.34%

95% CI −0.50 to 2.90

P = 0.04

By group

Ra-Ketamine vs S-Ketamine
risk difference 1.34% (95% CI −0.50 to 2.90); P = 0.04

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeRa-KetamineS-KetamineMedian difference (95% CI)P value
Morphine dose in the PACU10 (IQR 6–12) mg8 (IQR 6–10) mg1.00 (0.00–3.00)P = 0.02
PACU LOS105 (IQR 65–150) min100 (IQR 70–153) min−1.0 (−10.0 to 6.0)P = 0.70

Infusion strategy

Similar in both groups

Original publication

Tolerability and efficacy profile of S-ketamine compared with racemic ketamine in surgical patients, a prospective observational before-and-after study in the perioperative setting. BJA Open. Published 1 May 2026. doi:10.1016/j.bjao.2026.100548

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.